Lucosky Brookman Represents Medical Technology Pioneer NeurAxis in $5 Million Registered Direct Offering
In a significant advancement for pediatric neuromodulation therapy, NeurAxis, Inc. (NYSE American: NRXS) has successfully completed a $5 million registered direct offering, bolstering its commercial expansion following breakthrough FDA clearance for expanded treatment indications. The transaction, involving 1,538,461 shares of common stock at $3.25 per share, demonstrates strong investor confidence in the company's proprietary neuromodulation platform.
Under the guidance of Lucosky Brookman LLP, the financing provides NeurAxis with critical capital to capitalize on recent regulatory victories and market opportunities. The successful completion of this offering reflects growing market recognition of NeurAxis's innovative approach to treating chronic conditions through its IB-Stim™ technology.
The company plans to deploy the proceeds across several key initiatives:
- Commercial expansion of IB-Stim following FDA clearance for Pediatric Functional Abdominal Pain treatment
- Implementation of CPT Category I code, effective January 1, 2026
- Revenue growth acceleration and operational scaling
- Continued clinical development across multiple therapeutic applications
Combined with over $1 million obtained from recent warrant exercises, this financing strengthens NeurAxis's balance sheet as the company addresses significant unmet medical needs in pediatric care, particularly given the absence of FDA-approved drug therapies for children suffering from abdominal pain disorders linked to gut-brain interaction.
Lucosky Brookman LLP represented NeurAxis in the offering. Craig-Hallum Capital Group acted as the exclusive placement agent.
The closing of this offering represents a pivotal milestone in NeurAxis's mission to revolutionize neuromodulation therapy through its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.